Thus, CD40 signaling strongly activated canonical and non-canonical NF-κB signaling as well as Bcl-XL in both mutated and unmutated CLL patient samples, which led us to further investigate NF-κB-mediated drug resistance in the context of CD40 activation. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.